Novel EGFR‑bispecific recombinant immunotoxin based on cucurmosin shows potent anti‑tumor efficiency in vitro

Zhang,Caiyun; Cai,Yumei; Dai,Xiaoxue; Wu,Jingyu; Lan,Yinxiang; Zhang,Huajin; Lu,Mengni; Liu,Junhong; Xie,Jieming

doi:10.3892/or.2020.7878

Novel EGFR‑bispecific recombinant immunotoxin based on cucurmosin shows potent anti‑tumor efficiency in vitro

Authors:
- Caiyun Zhang
- Yumei Cai
- Xiaoxue Dai
- Jingyu Wu
- Yinxiang Lan
- Huajin Zhang
- Mengni Lu
- Junhong Liu
- Jieming Xie
View Affiliations

Affiliations: Department of Pharmacology, School of Pharmacy, Fujian Provincial Key Laboratory of Natural Medicine Pharmacology, Fujian Medical University, Fuzhou, Fujian 350122, P.R. China
Published online on: December 2, 2020 https://doi.org/10.3892/or.2020.7878
Pages: 493-500
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epidermal growth factor receptor (EGFR) is overexpressed in various tumors and is associated with cancer initiation, progression, and poor prognosis. Despite the achievements made by tyrosine kinase inhibitors and monoclonal antibodies in certain cases, many patients have not benefited from such treatment due to resistance. Immunotoxins (ITs) are antibody‑cytotoxin chimeric molecules with specific cell killing ability, which have achieved different degrees of success in the treatment of a wide range of cancers in clinical trials. The aim of the current study was to examine a novel targeting EGFR recombinant immunotoxin Bs/cucurmosin (CUS) generated by fusing CUS to the EGFR‑specific nanobody 7D12‑9G8. Bs/CUS was successfully expressed in Escherichia coli strain BL21 (DE3) in a soluble form. Furthermore, it retained binding capacity and specificity with EGFR and was superior to rE/CUS, a monospecific IT we reported previously. In vitro results showed that Bs/CUS could be internalized into the cytoplasm and selectively kill cells in the picomolar range. Flow cytometry showed that Bs/CUS killed the cells mediated by the apoptosis pathway. Taken together, results of the current study indicated that Bs/CUS is a promising candidate that should be further evaluated as a cancer therapeutic for the treatment of EGFR‑positive tumors.

View Figures

View References

1	Garrett TPJ, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Zhu HJ, Walker F, Frenkel MJ, Hoyne PA, et al: Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell. 110:763–773. 2002. View Article : Google Scholar : PubMed/NCBI
2	Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH, Saito K, Sakamoto A, Inoue M, Shirouzu M and Yokoyama S: Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell. 110:775–787. 2002. View Article : Google Scholar : PubMed/NCBI
3	Ciardiello F and Tortora G: EGFR antagonists in cancer treatment. N Engl J Med. 358:1160–1174. 2008. View Article : Google Scholar : PubMed/NCBI
4	Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, et al: Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes Dev. 21:2683–2710. 2007. View Article : Google Scholar : PubMed/NCBI
5	Morgillo F, Della Corte CM, Fasano M and Ciardiello F: Mechanisms of resistance to EGFR-targeted drugs: Lung cancer. ESMO Open. 1:e0000602016. View Article : Google Scholar : PubMed/NCBI
6	Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, et al: Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 486:532–536. 2012. View Article : Google Scholar : PubMed/NCBI
7	Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
8	Alewine C, Hassan R and Pastan I: Advances in anticancer immunotoxin therapy. Oncologist. 20:176–185. 2015. View Article : Google Scholar : PubMed/NCBI
9	Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R and Pastan I: Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. 30:1822–1828. 2012. View Article : Google Scholar : PubMed/NCBI
10	Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC and Pastan I: Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res. 13:5144–5149. 2007. View Article : Google Scholar : PubMed/NCBI
11	Kreitman RJ, Hassan R, Fitzgerald DJ and Pastan I: Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res. 15:5274–5279. 2009. View Article : Google Scholar : PubMed/NCBI
12	Mason-Osann E, Hollevoet K, Niederfellner G and Pastan I: Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results. Sci Rep. 5:108322015. View Article : Google Scholar : PubMed/NCBI
13	Mazor R, Crown D, Addissie S, Jang Y, Kaplan G and Pastan I: Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo. Cell Mol Immunol. 14:432–442. 2017. View Article : Google Scholar : PubMed/NCBI
14	Dennis MS, Zhang M, Meng YG, Kadkhodayan M, Kirchhofer D, Combs D and Damico LA: Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem. 277:35035–35043. 2002. View Article : Google Scholar : PubMed/NCBI
15	Siontorou CG: Nanobodies as novel agents for disease diagnosis and therapy. Int J Nanomedicine. 8:4215–4227. 2013. View Article : Google Scholar : PubMed/NCBI
16	Hou X, Meehan EJ, Xie J, Huang M, Chen M and Chen L: Atomic resolution structure of cucurmosin, a novel type 1 ribosome-inactivating protein from the sarcocarp of Cucurbita moschata. J Struct Biol. 164:81–87. 2008. View Article : Google Scholar : PubMed/NCBI
17	Zhang B, Huang H, Xie J, Xu C, Chen M, Wang C, Yang A and Yin Q: Cucurmosin induces apoptosis of BxPC-3 human pancreatic cancer cells via inactivation of the EGFR signaling pathway. Oncol Rep. 27:891–897. 2012.PubMed/NCBI
18	Xie J, Que W, Liu H, Liu M, Yang A and Chen M: Anti-proliferative effects of cucurmosin on human hepatoma HepG2 cells. Mol Med Rep. 5:196–201. 2012.PubMed/NCBI
19	Xie J, Wang C, Zhang B, Yang A, Yin Q, Huang H and Chen M: Cucurmosin induces the apoptosis of human pancreatic cancer CFPAC-1 cells by inactivating the PDGFR-β signalling pathway. Pharmacol Rep. 65:682–688. 2013. View Article : Google Scholar : PubMed/NCBI
20	Xie J, Wang C, Yang A, Zhang B, Yin Q, Huang H and Chen M: Cucurmosin kills human pancreatic cancer SW-1990 cells in vitro and in vivo. Anticancer Agents Med Chem. 13:952–956. 2013. View Article : Google Scholar : PubMed/NCBI
21	Deng C, Xiong J, Gu X, Chen X, Wu S, Wang Z, Wang D, Tu J and Xie J: Novel recombinant immunotoxin of EGFR specific nanobody fused with cucurmosin, construction and antitumor efficiency in vitro. Oncotarget. 8:38568–38580. 2017. View Article : Google Scholar : PubMed/NCBI
22	Roovers RC, Vosjan MJ, Laeremans T, el Khoulati R, de Bruin RC, Ferguson KM, Verkleij AJ, van Dongen GA and van Bergen en Henegouwen PM: A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. Int J Cancer. 129:2013–2024. 2011. View Article : Google Scholar : PubMed/NCBI
23	Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P and Green JA: First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev. CD0103832016.PubMed/NCBI
24	Jean GW and Shah SR: Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy. 28:742–754. 2008. View Article : Google Scholar : PubMed/NCBI
25	Lee JJ and Chu E: First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Clin Colorectal Cancer. 2 (Suppl 6):S42–S46. 2007. View Article : Google Scholar
26	Simon N and FitzGerald D: Immunotoxin therapies for the treatment of epidermal growth factor receptor-dependent cancers. Toxins (Basel). 8:1372016. View Article : Google Scholar
27	Cheung LS, Fu J, Kumar P, Kumar A, Urbanowski ME, Ihms EA, Parveen S, Bullen CK, Patrick GJ, Harrison R, et al: Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma. Proc Nat Acad Sci U S A. 116:3100–3105. 2019. View Article : Google Scholar
28	Xiong J, Zhang C, Wu S, Gu X, Cai Y, Xu C, Chen Z, Sun J, Wu X, You X, et al: Recombinant cucurmosin-based immunotoxin targeting HER-2 with potent in vitro anti-cancer cytotoxicity. Biochem Biophys Res Commun. 513:15–21. 2019. View Article : Google Scholar : PubMed/NCBI
29	Zhang C, Xiong J, Lan Y, Wu J, Wang C, Huang Z, Lin J and Xie J: Novel cucurmosin-based immunotoxin targeting programmed cell death 1-ligand 1 with high potency against human tumor in vitro and in vivo. Cancer Sci. 111:3184–3194. 2020. View Article : Google Scholar : PubMed/NCBI
30	Schmohl JU, Todhunter D, Taras E, Bachanova V and Vallera DA: Development of a deimmunized bispecific immunotoxin dDT2219 against B-cell malignancies. Toxins (Basel). 10:322018. View Article : Google Scholar
31	Sanz L, Blanco B and Alvarez-Vallina L: Antibodies and gene therapy: Teaching old ‘magic bullets’ new tricks. Trends Immunol. 25:85–91. 2004. View Article : Google Scholar : PubMed/NCBI
32	Roovers RC, Laeremans T, Huang L, De Taeye S, Verkleij AJ, Revets H, de Haard HJ and van Bergen en Henegouwen PMP: Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR nanobodies. Cancer Immunol Immunother. 56:303–317. 2007. View Article : Google Scholar : PubMed/NCBI
33	Tijink BM, Laeremans T, Budde M, Stigter-van Walsum M, Dreier T, de Haard HJ, Leemans CR and van Dongen GAMS: Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: Taking advantage of modular nanobody technology. Mol Cancer Ther. 7:2288–2297. 2008. View Article : Google Scholar : PubMed/NCBI